IPP Bureau
Crown Bioscience partners with Turbine to accelerate translational oncology research
By IPP Bureau - April 22, 2026
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
ProBioGen appoints Dr Simon Johannes Bulling as its new Chief Operating Officer
By IPP Bureau - April 22, 2026
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
New brain study reveals why alcohol relapse remains a persistent challenge
By IPP Bureau - April 22, 2026
These findings help explain how relapse-triggering memories can persist alongside those that support recovery
HCL Healthcare opens Bengaluru office to deepen enterprise client engagement
By IPP Bureau - April 22, 2026
New regional hub strengthens presence in a key market and enhances service delivery for corporate healthcare clients
New guardian protein mechanism identified in aggressive skin cancer progression
By IPP Bureau - April 22, 2026
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
ECI taps industry veteran Khalid Raja to drive strategic growth
By IPP Bureau - April 22, 2026
Move comes amid rising regulatory pressures
US FDA okays Merck's new once-daily HIV pill
By IPP Bureau - April 22, 2026
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Pfizer unleashes wave of breakthrough cancer data at ASCO 2026
By IPP Bureau - April 22, 2026
Pharma giant targets new standards of care
Asahi Kasei pushes into human trials with new autoimmune drug candidate
By IPP Bureau - April 22, 2026
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
Asahi Kasei seals Aicuris acquisition to bolster infectious disease pharma push
By IPP Bureau - April 22, 2026
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
Novo Nordisk’s Etavopivat delivers major Phase 3 win in sickle cell disease
By IPP Bureau - April 22, 2026
By cutting pain crises & boosting haemoglobin
Freudenberg Medical launches CleanAssure cleanroom for sterile single-use assemblies
By IPP Bureau - April 22, 2026
It is actually a new ISO Class 5 controlled cleanroom designed to deliver washed, dried, and gamma-sterilized single-use assemblies ready for immediate use.
Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion
By IPP Bureau - April 22, 2026
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
Astellas & Pfizer win FDA priority review for bladder cancer treatment expansion
By IPP Bureau - April 22, 2026
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
